Compare QSI & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSI | MSLE |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | 145 | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 146.9M |
| IPO Year | N/A | N/A |
| Metric | QSI | MSLE |
|---|---|---|
| Price | $0.76 | $6.19 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 103.1K |
| Earning Date | 03-03-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $6.67 |
| 52 Week High | $3.10 | $13.39 |
| Indicator | QSI | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 26.32 |
| Support Level | N/A | N/A |
| Resistance Level | $1.11 | $8.37 |
| Average True Range (ATR) | 0.06 | 0.88 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 0.88 | 2.25 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.